HRP20210299T1 - Inhibitori histonske demetilaze - Google Patents
Inhibitori histonske demetilaze Download PDFInfo
- Publication number
- HRP20210299T1 HRP20210299T1 HRP20210299TT HRP20210299T HRP20210299T1 HR P20210299 T1 HRP20210299 T1 HR P20210299T1 HR P20210299T T HRP20210299T T HR P20210299TT HR P20210299 T HRP20210299 T HR P20210299T HR P20210299 T1 HRP20210299 T1 HR P20210299T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- aryl
- alkyl
- heteroaryl
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017201P | 2014-06-25 | 2014-06-25 | |
| PCT/US2015/037812 WO2015200709A1 (en) | 2014-06-25 | 2015-06-25 | Histone demethylase inhibitors |
| EP15811523.8A EP3160952B1 (en) | 2014-06-25 | 2015-06-25 | Histone demethylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210299T1 true HRP20210299T1 (hr) | 2021-04-16 |
Family
ID=54929774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210299TT HRP20210299T1 (hr) | 2014-06-25 | 2015-06-25 | Inhibitori histonske demetilaze |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US9242968B2 (enExample) |
| EP (3) | EP3160952B1 (enExample) |
| JP (1) | JP6521535B2 (enExample) |
| KR (1) | KR102591897B1 (enExample) |
| CN (2) | CN111909083B (enExample) |
| AR (1) | AR100997A1 (enExample) |
| AU (1) | AU2015279719B2 (enExample) |
| BR (1) | BR112016030367A2 (enExample) |
| CA (1) | CA2953437C (enExample) |
| CL (1) | CL2016003301A1 (enExample) |
| CO (1) | CO2017000359A2 (enExample) |
| CY (1) | CY1123906T1 (enExample) |
| DK (1) | DK3160952T3 (enExample) |
| EA (1) | EA031200B1 (enExample) |
| EC (1) | ECSP17004931A (enExample) |
| ES (1) | ES2862648T3 (enExample) |
| HR (1) | HRP20210299T1 (enExample) |
| HU (1) | HUE053876T2 (enExample) |
| IL (1) | IL249629A0 (enExample) |
| LT (1) | LT3160952T (enExample) |
| MX (1) | MX375219B (enExample) |
| NZ (1) | NZ728120A (enExample) |
| PL (1) | PL3160952T3 (enExample) |
| PT (1) | PT3160952T (enExample) |
| SA (1) | SA516380585B1 (enExample) |
| SG (1) | SG11201610813TA (enExample) |
| SI (1) | SI3160952T1 (enExample) |
| TW (2) | TWI715533B (enExample) |
| WO (1) | WO2015200709A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2895808A1 (en) * | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| MX375219B (es) | 2014-06-25 | 2025-03-06 | Celgene Quanticel Res Inc | Inhibidores de histona demetilasa. |
| EP3453710B1 (en) | 2014-09-17 | 2022-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10059687B2 (en) * | 2015-12-28 | 2018-08-28 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2017161012A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US20200039938A1 (en) | 2017-03-30 | 2020-02-06 | Albert-Ludwigs-University Freiburg | Kdm4 inhibitors |
| CN109825551B (zh) * | 2019-02-21 | 2022-08-02 | 深圳大学 | 一种评价组蛋白赖氨酸去甲基转移酶活性的方法 |
| CN111679072B (zh) * | 2020-06-15 | 2022-04-29 | 温州医科大学 | Kdm6b蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用 |
| EP4319748A4 (en) * | 2021-04-09 | 2025-02-26 | Tachyon Therapeutics, Inc. | TREATMENT OF CANCER WITH KDM4 INHIBITORS |
| JP2024531115A (ja) * | 2021-08-18 | 2024-08-29 | セルジーン コーポレーション | ヒストン脱メチル化阻害剤を調製するためのプロセス |
| EP4452249A4 (en) * | 2021-12-23 | 2026-03-11 | Tachyon Therapeutics Inc | PHARMACEUTICAL FORMULATIONS COMPRISING 3-({[(4R)-7-{METHYL[4-(PROPAN-2-YL)PHENYL]AMINO}-3,4-DIHYDRO-2H-L-BENZOPYRAN-4-YL]METHYL}AMINO)PYRIDINE-4-CARBOXYLIC ACID |
| AR129578A1 (es) | 2022-06-10 | 2024-09-11 | Forward Therapeutics Inc | MODULADORES DE LA ACTIVIDAD DE TNF-a |
| AU2023288541A1 (en) * | 2022-06-23 | 2025-02-06 | The Cleveland Clinic Foundation | 3-βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF |
| AU2023347942A1 (en) * | 2022-09-21 | 2025-04-10 | Celgene Corporation | Crystalline forms of 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-1-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid l-lysine salt, a histone demethylase inhibitor |
| CN115974647B (zh) * | 2022-12-05 | 2024-09-03 | 江苏宏邦化工科技有限公司 | 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法 |
| WO2025085527A1 (en) * | 2023-10-16 | 2025-04-24 | The Cleveland Clinic Foundation | 3βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024448A2 (en) * | 2001-09-14 | 2003-03-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004039876A1 (de) | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| ES2452820T3 (es) * | 2006-04-07 | 2014-04-02 | Methylgene, Inc. | Derivados de benzamida como inhibidores de histona desacetilasa |
| US7898712B2 (en) | 2008-06-27 | 2011-03-01 | Lockheed Martin Corporation | Risley integrated steering module |
| GB201112607D0 (en) * | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| EP2701699B1 (en) | 2011-04-28 | 2019-10-16 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| WO2013143597A1 (en) * | 2012-03-29 | 2013-10-03 | Glaxo Group Limited | Demethylase enzymes inhibitors |
| WO2014089368A1 (en) | 2012-12-05 | 2014-06-12 | Bio-Rad Laboratories, Inc | Methods for polymerase chain reaction copy number variation assays |
| WO2014089364A1 (en) * | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc | Histone demethylase inhibitors |
| HUE037312T2 (hu) | 2012-12-19 | 2018-08-28 | Celgene Quanticel Res Inc | Hiszton demetiláz inhibitorok |
| CA2895808A1 (en) | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| MX375219B (es) | 2014-06-25 | 2025-03-06 | Celgene Quanticel Res Inc | Inhibidores de histona demetilasa. |
| US20200039938A1 (en) * | 2017-03-30 | 2020-02-06 | Albert-Ludwigs-University Freiburg | Kdm4 inhibitors |
-
2015
- 2015-06-25 MX MX2016017407A patent/MX375219B/es active IP Right Grant
- 2015-06-25 CN CN202010813617.0A patent/CN111909083B/zh active Active
- 2015-06-25 EP EP15811523.8A patent/EP3160952B1/en active Active
- 2015-06-25 WO PCT/US2015/037812 patent/WO2015200709A1/en not_active Ceased
- 2015-06-25 US US14/751,007 patent/US9242968B2/en active Active
- 2015-06-25 ES ES15811523T patent/ES2862648T3/es active Active
- 2015-06-25 PL PL15811523T patent/PL3160952T3/pl unknown
- 2015-06-25 KR KR1020177002223A patent/KR102591897B1/ko active Active
- 2015-06-25 DK DK15811523.8T patent/DK3160952T3/da active
- 2015-06-25 HU HUE15811523A patent/HUE053876T2/hu unknown
- 2015-06-25 BR BR112016030367A patent/BR112016030367A2/pt not_active Application Discontinuation
- 2015-06-25 HR HRP20210299TT patent/HRP20210299T1/hr unknown
- 2015-06-25 AU AU2015279719A patent/AU2015279719B2/en active Active
- 2015-06-25 US US15/321,702 patent/US10385047B2/en active Active
- 2015-06-25 NZ NZ728120A patent/NZ728120A/en unknown
- 2015-06-25 AR ARP150102042A patent/AR100997A1/es not_active Application Discontinuation
- 2015-06-25 LT LTEP15811523.8T patent/LT3160952T/lt unknown
- 2015-06-25 EP EP20184107.9A patent/EP3738960A1/en not_active Withdrawn
- 2015-06-25 CA CA2953437A patent/CA2953437C/en active Active
- 2015-06-25 SG SG11201610813TA patent/SG11201610813TA/en unknown
- 2015-06-25 EA EA201692483A patent/EA031200B1/ru unknown
- 2015-06-25 TW TW104120633A patent/TWI715533B/zh active
- 2015-06-25 CN CN201580045921.2A patent/CN106660982B/zh active Active
- 2015-06-25 EP EP20184106.1A patent/EP3741749A1/en active Pending
- 2015-06-25 PT PT158115238T patent/PT3160952T/pt unknown
- 2015-06-25 TW TW109143458A patent/TWI758004B/zh active
- 2015-06-25 JP JP2016574454A patent/JP6521535B2/ja active Active
- 2015-06-25 SI SI201531524T patent/SI3160952T1/sl unknown
- 2015-12-09 US US14/963,754 patent/US9447046B2/en active Active
-
2016
- 2016-07-26 US US15/220,118 patent/US9586902B2/en active Active
- 2016-12-18 IL IL249629A patent/IL249629A0/en unknown
- 2016-12-22 CL CL2016003301A patent/CL2016003301A1/es unknown
- 2016-12-22 SA SA516380585A patent/SA516380585B1/ar unknown
-
2017
- 2017-01-09 US US15/402,100 patent/US9815828B2/en active Active
- 2017-01-16 CO CONC2017/0000359A patent/CO2017000359A2/es unknown
- 2017-01-24 EC ECIEPI20174931A patent/ECSP17004931A/es unknown
- 2017-10-24 US US15/792,570 patent/US9994561B2/en active Active
-
2018
- 2018-05-04 US US15/971,749 patent/US10106534B2/en active Active
-
2021
- 2021-03-01 CY CY20211100169T patent/CY1123906T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA518400660B1 (ar) | مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2 | |
| PH12018501179A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| TR201903322T4 (tr) | Kinaz inhibisyonu için heteroaril bileşikleri. | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
| EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
| MD4779B1 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| BR112016029846A2 (pt) | ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo? | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
| HUE070489T2 (hu) | Lanifibranor deuterizált származékainak terápiás alkalmazása | |
| EA201692512A1 (ru) | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки | |
| MX369369B (es) | Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| NZ629037A (en) | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same | |
| JP2017523152A5 (enExample) | ||
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| EA201401082A1 (ru) | Фармацевтические препараты, содержащие антагонисты ccr3 | |
| EA201790847A1 (ru) | Композиции и способы лечения с применением пролекарств тизоксанида, его аналога или соли | |
| EA201790327A1 (ru) | Соединения замещенного пиперидина | |
| BR112016011016A8 (pt) | derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica. |